Support our Foundation of Myology project
NMD670
A phase 2a, randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of NMD670 over 21 days in ambulatory adult patients with Charcot-Marie-Tooth disease type 1 and type 2.